The discussion will dissect the specific hurdles inherent in modern clinical research, where identifying patients with precise genetic mutations remains a primary bottleneck. Experts, including Chloe Rose of Pratia and Dr. Julio Peguero, will examine how referral pathways and site capabilities must be calibrated to meet the distinct demands of Phase I versus later-phase studies.

Beyond technical recruitment, the session will contrast the operational landscapes of the US and European markets. By identifying barriers during the start-up phase, sponsors and CROs can improve site readiness and move toward more predictable enrollment cycles. Interested professionals can register for the live event, scheduled for 10:00 am EDT, to gain insights into bridging the gap between protocol design and patient access.